title: Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.
authors.affiliation: From the Duke Clinical Research Institute (K.A.S., S.D.R.) and the Duke Institute for Health Innovation (S.B.), Duke Translational Medicine Institute, and the Department of Medicine (K.A.S., S.D.R.), Duke University School of Medicine, Durham, NC.
authors.forename: Kevin A
authors.initials: KA
authors.lastname: Schulman
authors.forename: Suresh
authors.initials: S
authors.lastname: Balu
authors.forename: Shelby D
authors.initials: SD
authors.lastname: Reed
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents / Q000191:economics* / Q000627:therapeutic use; D017277:Drug Approval; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D007341:Insurance; D007348:Insurance, Health / Q000191:economics*; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors*; D012697:Serine Endopeptidases; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases; C577155:evolocumab; C571059:alirocumab